TCT 2016: EXCEL, NOBLE present conflicting findings on eluting stents, bypass surgery

Two new trials on eluting heart stents designed to treat unprotected left main coronary artery disease were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 conference, and they have left cardiologists stumped over their conflicting findings.

In one trial titled Excel, Gregg W. Stone, MD, the director of cardiovascular research and education at Columbia University Medical Center in New York, and his team conducted a trial comparing Abbott Vascular’s Xience everolimus-eluting metallic stent to a coronary artery bypass graft (CABG) surgery in patients with left main coronary artery disease. The full study was published online Oct. 31 in the New England Journal of Medicine.

Results showed that patients with low or intermediate SYNTAX scores with Xience implants had fewer adverse events 30 days after the procedure and comparable rates of stroke, death and MI after three years.

"A stenting procedure with Xience may be an acceptable way to increase blood flow to the heart for certain patients with left main coronary artery disease, taking into account a patient's individual circumstances," said Charles A. Simonton, MD, chief medical officer for Abbott's vascular business, in a statement to Cardiovascular Business. "This is important news for patients because in addition to improved safety, stenting procedures are much less invasive than open heart surgery, potentially reducing recovery time and healthcare costs." 

But the Excel findings contradict those in a separate study titled Noble, done by Evald H. Christiansen, MD, PhD, a cardiologist at Aarhus University Hospital in Denmark.

The Noble study, published Oct. 31 in the Lancet, compared the effectiveness of a Biomatrix Flex biolimus-eluting stent to bypass graft surgery. Results showed that patients had higher rates of adverse cardiac and cerebrovascular events after five years when compared with a CABG surgery. Additionally, stroke rates were higher among patients who underwent a CABG procedure at 30 days, but were numerically higher among patients with the stent after five years.

With the Excel study making a case that PCI may be a better treatment option over CABG for patients with left main coronary artery disease and Noble saying the opposite, cardiologists are left to wonder what that means for practice going forward.

David J. Cohen, MD, a cardiologist at Saint Luke’s Health System in Kansas City, Missouri, said at a TCT press conference that though the trials conflict with each other in certain areas, there are still significant similarities.

“I don’t see them as quite so different,” Cohen said. “I think the biggest difference is the striking finding that the SYNTAX score didn’t seem to matter, which was very surprising based on the data from the SYNTAX trial where it seemed to work so well, and I think that needs to be examined more closely.”

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup